Tue, Sep 23, 2014, 12:49 PM EDT - U.S. Markets close in 3 hrs 11 mins

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • alabamatigers11u alabamatigers11u Jan 31, 2013 10:12 AM Flag

    Maybe drop yesterday was just a bio thing?

    Many bio's dropped bad yesterday, and NVIV was up about 70% in a short time, so it got whacked too. May not be anything to do with company, but just the sector. As for interesting plays today, CLSN down 85% if you like to [play bounces, and VRNG just added Microsoft to their list of big boys they are suing. VRNG could absolutely start flying soon, as some of their cases start settling. Long NVIV, I freed up about 4K yesterday and will put it here when it settles if NVIV still close to $2, glta longs.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Due to the further decline by NVIV today, I now believe that it is mostly due to not hitting Jan 31 target by FDA, as was predicted by NVIV. Most likely no big deal and probably creating another great buying opp in NVIV. As I understand it, it's not reasonable to expect bad news, but rather the FDA and NVIV have a dialogue between them about meeting the requirements to start the human trials. So worst case, delay until requirements are met?? Am I right?

      Sentiment: Strong Buy

    • CLSN was make it or break it. At this point i would rather own NVIV than CLSN. They have one and the same technology for all trials. It is named Lysolipid Thermally Sensitive Liposomes (LTSL) and when that one did not work with liver, it will probably not work with other pipeline research as well (breast cancer, prostate etc.)

 
NVIV
0.5357+0.0057(+1.08%)12:32 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.